Enhancing and maintaining a culture of inclusive excellence: The NIH FIRST Program
Inherent in the mission of NIH is that biomedical research and its application can and should benefit all people
Nora's Blog
FDA Approves First Drug Derived from Marijuana
|
This week, the Food and Drug Administration (FDA) approved Epidiolex (cannabidiol, or CBD), a medication extracted from marijuana, for the treatment of two severe pediatric seizure disorders.
3 Comments
An Ambitious Research Plan to Help Solve the Opioid Crisis
|
In spring 2018, Congress added an additional $500 million to the NIH budget to invest in science to find solutions to the opioid crisis. The funding that NIDA is receiving...
NIDA-Supported Science Leads to First FDA-Approved Medication for Opioid Withdrawal
|
This week, the Food and Drug Administration (FDA) approved lofexidine, the first medication targeted specifically to treat the physical symptoms associated with opioid withdrawal.
Million-Participant NIH Study Could Yield Important Insights into Addiction and Pain
|
New data-gathering and analytic capabilities are enabling the kinds of massive, long-term studies needed to investigate genetic, environmental, and lifestyle factors that contribute to disease.
The True, Deadly Scope of America’s Fentanyl Problem
|
Today, a new analysis in JAMA by epidemiologists at NIDA and the Substance Abuse and Mental Health Services Administration reveals the scope of the crisis, and the rapidity with which...
Listening to Patients’ Voices in Developing New Opioid Addiction Treatments
|
One of the pillars of the current federal initiatives to end the opioid crisis is the development of new medications to treat opioid addiction. The FDA Patient-Focused Drug Development Initiative...
What Does It Mean When We Call Addiction a Brain Disorder?
|
Informed Americans no longer view addiction as a moral failing, and more and more policymakers are recognizing that punishment is an ineffective and inappropriate tool for addressing a person’s drug...
Could Naltrexone Be Used to Treat Pregnant Women with Opioid Addiction?
|
A recent study published in Lancet found that extended-release naltrexone was equally effective at reducing illicit opioid use as the partial agonist buprenorphine if patients could be successfully initiated on...
NIDA’s Past-Year Achievements Point the Way Toward Future Advances
|
2017 brought exciting new basic science findings, including some striking new insights into the structure and functioning of receptors that play important roles in substance use, addiction, and pain.
Monitoring the Future Results Show Reduced Opioid Misuse but Popularity of Vaping Among Youth
|
Today the results of the 2017 Monitoring the Future (MTF) survey were released by NIDA-funded researchers at the University of Michigan at Ann Arbor, and overall the news is encouraging.
